BASILEA PHARMACEUTICA-REG
BASILEA PHARMACEUTICA-REG/ CH0011432447 /
BSLN/Z
23.05.2024 17:15:55
|
Zm.
+0,95
|
Wolumen |
Bid- |
Ask- |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
44,20CHF
|
+2,20%
|
361 Obrót: 16 042,85 |
-Wolumen Bid: - |
-Wolumen Ask: - |
578,36 mlnCHF |
- |
50,75 |
Opis działalności
Basilea Pharmaceutica AG, founded in 2000, is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. The company has a portfolio of marketed drugs: Zevtera®/Mabelio® (ceftobiprole) is an intravenous antibiotic from the cephalosporin class amd Cresemba® (isavuconazole) is an intravenous and oral antifungal from the azole class. Furthermore Basilea's pipeline includes three early-stage oncology drug candidates. Basilea Pharmaceutica AG is headquartered in Basel, Switzerland.
Zarząd & Rada nadzorcza
CEO |
David Veitch |
Zarząd |
Adesh Kaul, Dr. Gerrit Hauck, Dr. Laurenz Kellenberger, Dr. Marc Engelhardt |
Rada nadzorcza |
Domenico Scala, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Thomas Werner, Ronald Scott, Steven D. Skolsky |
Dane firmy
Nazwa: |
Basilea Pharmaceutica AG |
Adres: |
Grenzacherstraße 487,CH-4005 Basel |
Telefon: |
+41-61-606-1111 |
Fax: |
+41-61-606-1112 |
E-mail: |
info_basilea@basilea.com
|
Internet: |
www.basilea.com |
Przemysł: |
Służba zdrowia |
Sektor: |
Przemysł Farmaceutyczny |
Podsektor: |
Przemysł Farmaceutyczny |
Koniec roku finansowego: |
31.12 |
Free float: |
90,35% |
Data IPO: |
25.03.2004 |
Kalendarz korporacyjny
Tydz. 33 | 13.08.2024
Raport okresowy/2. kwartał
|